The effect of treatment with the oral growth hormone (GH) secretagogue MK-677 on GH isoforms

2003 ◽  
Vol 13 (1) ◽  
pp. 1-7 ◽  
Author(s):  
J. Svensson ◽  
C.L. Boguszewski ◽  
F. Shibata ◽  
B. Carlsson ◽  
L.M.S. Carlsson ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Gh Isoforms ◽  
Effect Of Treatment

The influence of dietary monensin and salinomycin on growth and endocrine status of gilts

1992 ◽  
Vol 72 (2) ◽  
pp. 427-429 ◽  
Author(s):  
T. A. Van Lunen ◽  
R. N. Kirkwood ◽  
P. A. Thacker
Keyword(s):  
Growth Hormone ◽  
Body Weight ◽  
Key Words ◽  
Crude Protein ◽  
Protein Diet ◽  
Serum Growth Hormone ◽  
Endocrine Status ◽  
Effect Of Treatment

Seventy-two gilts were fed a 16% crude protein diet supplemented with monensin, salinomycin or not supplemented. There was no effect of treatment on gilt growth between 30 and 100 kg body weight. Monensin-fed gilts tended to have increased, while salinomycin-fed gilts had decreased (P < 0.01), serum growth hormone concentrations. Salinomycin-fed gilts were older and heavier at puberty (P < 0.05). Key words: Monensin, salinomycin, gilts, growth, reproduction

No effect of treatment with sodium valproate on plasma growth hormone in bromocriptine unresponsive acromegaly

1986 ◽  
Vol 111 (2) ◽  
pp. 162-164 ◽  
Author(s):  
J. W. R. Nortier ◽  
R.J. M. Croughs ◽  
F. Schwarz ◽  
J. H. H. Thijssen
Keyword(s):  
Growth Hormone ◽  
Clinical Improvement ◽  
Sodium Valproate ◽  
Pituitary Surgery ◽  
Plasma Growth Hormone ◽  
Favourable Response ◽  
The Past ◽  
Effect Of Treatment

Abstract. Administration of sodium valproate for 6 months at a dose of 300 mg three times daily to 7 bromocriptine unresponsive acromegalic patients who all but one had been treated with pituitary surgery and/or radiotherapy in the past did not result in a significant reduction of the plasma growth hormone (GH) level or in any clinical improvement. It is concluded that sodium valproate is not suitable for the treatment of acromegalic patients who do not show a favourable response to bromocriptine.

scholarly journals Effect of treatment with octreotide on the morphology of growth hormone—secreting pituitary adenomas: Study of 24 cases

1991 ◽  
Vol 2 (3) ◽  
pp. 123-131 ◽  
Author(s):  
Albert Beckers ◽  
Kalman Kovacs ◽  
Eva Horvath ◽  
Roger Abs ◽  
Michel Reznik ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Pituitary Adenomas ◽  
Effect Of Treatment

The effect of treatment with growth hormone on fertility outcome in eugonadal women with growth hormone deficiency: report of four cases and review of the literature

2009 ◽  
Vol 91 (3) ◽  
pp. 930.e7-930.e11 ◽  
Author(s):  
Antonella Giampietro ◽  
Domenico Milardi ◽  
Antonio Bianchi ◽  
Alessandra Fusco ◽  
Vincenzo Cimino ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Growth Hormone Deficiency ◽  
Hormone Deficiency ◽  
Review Of The Literature ◽  
Effect Of Treatment

Interassay Differences in Growth Hormone Measurement in Acromegaly

1997 ◽  
Vol 34 (2) ◽  
pp. 156-159 ◽  
Author(s):  
J H Barth ◽  
J H Smith ◽  
P Clarkson
Keyword(s):  
Growth Hormone ◽  
Mean Value ◽  
Consistent Difference ◽  
Plasma Samples ◽  
Plasma Growth Hormone ◽  
Gh Isoforms ◽  
The Mean ◽  
Good Agreement

We measured plasma growth hormone concentrations by three different two-site immunometric assays (Pharmacia hGH RIA, IDS Gamma-BCT and Delfia 22 kDa hGH) to determine whether there are GH isoforms secreted by acromegalic patients that are under-recognized by some assays. There was a fairly good agreement between assays with the IDS Gamma-BCT and Delfia 22 kDa assays giving lower results than the Pharmacia IRMA. GH was measured on stored plasma samples from 24 patients with proven acromegaly. There was a consistent difference between the three assays of approximately 20% of the mean value for each patient.

Unaltered ratio of circulating levels of growth hormone/GH isoforms in adults with Prader–Willi syndrome after GHRH plus arginine administration

2015 ◽  
Vol 25 (4) ◽  
pp. 168-173 ◽  
Author(s):  
A.E. Rigamonti ◽  
G. Grugni ◽  
N. Marazzi ◽  
S. Bini ◽  
M. Bidlingmaier ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Prader Willi Syndrome ◽  
Gh Isoforms ◽  
Circulating Levels

scholarly journals Challenges in Detecting the Abuse of Growth Hormone in Sport

2005 ◽  
Vol 51 (9) ◽  
pp. 1587-1593 ◽  
Author(s):  
Cathy M McHugh ◽  
Roderick T Park ◽  
Peter H Sönksen ◽  
Richard IG Holt
Keyword(s):  
Growth Hormone ◽  
Anabolic Steroids ◽  
Reference Interval ◽  
Naturally Occurring ◽  
Gh Isoforms ◽  
Comprehensive Search ◽  
World Anti Doping Agency ◽  
Academic Interests ◽  
Substances Of Abuse ◽  
Future Concepts

Abstract Background: Growth hormone (GH) is reputed to be in widespread use in the sporting arena as a performance-enhancing agent and is on the list of banned substances published by the World Anti-Doping Agency. The detection of GH abuse poses many challenges. Unlike many substances of abuse, such as synthetic anabolic steroids, GH is a naturally occurring substance; therefore, demonstration of exogenous administration must rely on detecting concentrations in excess of an established reference interval. The purpose of this review is to discuss the methodologies being developed to detect GH abuse. Methods: We undertook a comprehensive search using multiple electronic databases and hand searches of reference lists of articles. The data for this review reflect our academic interests and experience through work on the GH-2000 and GH-2004 projects. Results: Two approaches have been taken to detect GH abuse. The first is based on assessment of the effect of exogenous GH on pituitary GH isoforms, and the second is based on measurement of markers of GH action. The advantages of each approach and the difficulties encountered with each technique, as well as future concepts in detection, are discussed. Conclusion: Although there are substantial challenges for the detection of GH, methodologies now exist to detect GH abuse with reasonable sensitivity and specificity.

Sign in / Sign up

Export Citation Format

Share Document